Journal of Thoracic Oncology

1

Lung Cancer in Malaysia

Rajadurai, Pathmanathan, How, Soon Hin, Liam, Chong Kin, Sachithanandan, Anand, Soon, Sing Yang, Tho, Lye Mun

Journal:

Année:

2020

Langue:

english

Fichier:

PDF, 402 KB

english, 2020

2

Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia

Fang, Wenfeng, Huang, Yihua, Gan, Jiadi, He, Bishan, Zhang, Li

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 634 KB

2020

3

TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma

Mao, Weijun, Chen, Ruo, Zhang, Junling, Zheng, Mingfeng

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 356 KB

2020

4

Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC

Zhang, Qian, Jiang, Ting, Xiao, Mingzhe, Zhang, Junling, Ying, Xiaowei

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 1.52 MB

2020

5

Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitorâthe End or Beginning?

De-Rui Huang, Derek, Chih-Hsin Yang, James

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 160 KB

2020

6

Tocilizumab for Fulminant Programmed Death 1 InhibitorâAssociated Myocarditis

Wang, Hanping, Tian, Ran, Gao, Peng, Wang, Qian, Zhang, Li

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 173 KB

2020

7

Dual Inhibition of EGFR and BRAF Can Be Harmful in Patients Harboring an EGFR-Activating Mutation

Oh, Sekyung, Lim, Jun Hyeok, Park, Nuri, Choi, Seohee, Ryu, Jeong-Seon

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 147 KB

2020

8

Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy

Fang, Wenfeng, Huang, Yihua, Gan, Jiadi, Zheng, Qiufan, Zhang, Li

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 656 KB

2020

9

PD-1 Blockers: Staying Long in the Body and Delayed Toxicity Risks

Fukudo, Masahide, Sasaki, Takaaki, Ohsaki, Yoshinobu

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 548 KB

2020

10

Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations

Macaya, Irati, Entrialgo-Cadierno, Rodrigo, Valencia, Karmele, Vicent, Silvestre

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 174 KB

2020

11

Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?

Menis, Jessica, Reck, Martin

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 164 KB

2020

12

In This Issue/Research Watch/News in Brief/News from the IASLC Tobacco Control Committee

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 1.05 MB

2020

13

Managing the Isolated Central Nervous System Progression in Patients With Oncogene-Driven Metastatic NSCLC: Does Circulating Tumor DNA Add to Management?

Li, Tianhong

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 160 KB

2020

14

Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma

Wang, Leiming, Yao, Shuyang, Teng, Lianghong, Zhang, Weiwei, Chen, Li

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 1.61 MB

2020

15

Board of Directors

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 149 KB

2020

16

Editorial Board

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 161 KB

2020

17

Meeting Announcements

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 64 KB

2020

18

Severe Immune-Related Hepatitis Treated With Plasma Exchange

Kanemura, Hiroaki, Hayashi, Hidetoshi, Hagiwara, Satoru, Otani, Tomoyuki, Haratani, Koji, Yonesaka, Kimio, Ito, Akihiko, Kudo, Masatoshi, Nakagawa, Kazuhiko

Journal:

Journal of Thoracic Oncology

Année:

2020

Fichier:

PDF, 982 KB

2020

Volume 15; Issue 3

Lung Cancer in Malaysia

Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia

TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma

Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC

Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitorâthe End or Beginning?

Tocilizumab for Fulminant Programmed Death 1 InhibitorâAssociated Myocarditis

Dual Inhibition of EGFR and BRAF Can Be Harmful in Patients Harboring an EGFR-Activating Mutation

Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy

PD-1 Blockers: Staying Long in the Body and Delayed Toxicity Risks

Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations

Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?

In This Issue/Research Watch/News in Brief/News from the IASLC Tobacco Control Committee

Managing the Isolated Central Nervous System Progression in Patients With Oncogene-Driven Metastatic NSCLC: Does Circulating Tumor DNA Add to Management?

Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma

Board of Directors

Editorial Board

Meeting Announcements

Table of Contents

Severe Immune-Related Hepatitis Treated With Plasma Exchange